JP2013535963A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535963A5
JP2013535963A5 JP2013519215A JP2013519215A JP2013535963A5 JP 2013535963 A5 JP2013535963 A5 JP 2013535963A5 JP 2013519215 A JP2013519215 A JP 2013519215A JP 2013519215 A JP2013519215 A JP 2013519215A JP 2013535963 A5 JP2013535963 A5 JP 2013535963A5
Authority
JP
Japan
Prior art keywords
seq
diabetes
isolated
complex
high affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013519215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2011/000563 external-priority patent/WO2012007950A2/en
Publication of JP2013535963A publication Critical patent/JP2013535963A/ja
Publication of JP2013535963A5 publication Critical patent/JP2013535963A5/ja
Pending legal-status Critical Current

Links

JP2013519215A 2010-07-15 2011-07-14 Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体 Pending JP2013535963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36443710P 2010-07-15 2010-07-15
US61/364,437 2010-07-15
PCT/IL2011/000563 WO2012007950A2 (en) 2010-07-15 2011-07-14 Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides

Publications (2)

Publication Number Publication Date
JP2013535963A JP2013535963A (ja) 2013-09-19
JP2013535963A5 true JP2013535963A5 (https=) 2014-08-28

Family

ID=44504047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013519215A Pending JP2013535963A (ja) 2010-07-15 2011-07-14 Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体

Country Status (5)

Country Link
US (1) US20130189284A1 (https=)
EP (1) EP2593480A2 (https=)
JP (1) JP2013535963A (https=)
CA (1) CA2805478A1 (https=)
WO (1) WO2012007950A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007951A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
AU2015321365B2 (en) * 2014-09-26 2021-05-20 The University Of British Columbia A combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation
EP3221344A2 (en) * 2014-11-21 2017-09-27 Immusant Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
GB201506112D0 (en) * 2015-04-10 2015-05-27 Midatech Ltd And Inst Nationale De La Sant� Et De Al Rech Medicale And University College Car Nanoparticle-based antigen specific immunotherapy
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
JP7057748B2 (ja) 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520603D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
US12153056B2 (en) 2019-07-15 2024-11-26 Washington University Compositions for and methods of diagnosing, prognosing, and treating diabetes
EP4384603A1 (en) 2021-08-10 2024-06-19 Gamida-Cell Ltd. Engineered nk cells, methods of their production and uses thereof
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i
US20260041747A1 (en) * 2022-07-29 2026-02-12 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
DE19525784A1 (de) 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
EP0869815A1 (en) * 1995-09-21 1998-10-14 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
US6037137A (en) 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
DK1017721T3 (da) * 1997-09-16 2009-04-20 Univ Oregon Health & Science Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler
US20030166277A1 (en) 2000-04-12 2003-09-04 University Of Rochester Targeted vaccine delivery systems
DE60129572T2 (de) * 2000-08-14 2008-04-17 N.V. Organon Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
US8314210B2 (en) * 2002-07-12 2012-11-20 Dana-Farber Cancer Institute, Inc. Compositions and methods for the generation of MHC class II compounds by peptide exchange
WO2006007667A1 (en) * 2004-07-23 2006-01-26 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostic agents
AU2006227368A1 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant MHC molecules useful for manipulation of antigen-specific T cells
AU2008222678B2 (en) 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions

Similar Documents

Publication Publication Date Title
JP2013535963A5 (https=)
JP2013538555A5 (https=)
CA2861793C (en) Method of providing monoclonal auto-antibodies with desired specificity
JP2012143232A5 (https=)
JP2018527884A5 (https=)
JP2021535733A5 (https=)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
JP2021107397A (ja) 抗ｉｌ２３抗体を使用してクローン病を治療するための方法
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2018166506A5 (https=)
JP2018512145A5 (https=)
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
CA2792740A1 (en) Antibodies with ph dependent antigen binding
JP2019515646A (ja) Ｐｄ−ｌ１に対する結合メンバー
JP2010511388A5 (https=)
FI3309176T3 (fi) Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö
JP2017529067A5 (https=)
US10131709B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
JP2012531212A5 (https=)
JP2014526898A5 (https=)
JP2018502060A5 (https=)
RU2017134140A (ru) Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования
HRP20220553T1 (hr) Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
JP2012501670A5 (https=)
JP2016503412A5 (ja) Ｉｌ−６アンタゴニストおよびその使用